Cohn Stephen M
Division of Trauma, Daughtry Family Department of Surgery, University of Miami School of Medicine, Miami, Florida, USA.
Crit Care. 2004;8 Suppl 2(Suppl 2):S15-7. doi: 10.1186/cc2412. Epub 2004 Jun 14.
Persons who suffer traumatic injury are likely to be transfused with considerable amounts of blood during initial resuscitation efforts. Oxygen-carrying solutions are currently in clinical testing as substitutes for red blood cells. Although these agents may eliminate many concerns associated with blood administration (short shelf life, infectious and immunologic risks, the need to type and cross-match), early cell-free hemoglobin solutions demonstrated nephrotoxicity and were associated with pulmonary and systemic hypertension, among other adverse events. Newer polymerized hemoglobin solutions show acceptable safety profiles in the surgical setting and studies are being designed, some with funding from the US Department of Defense, to evaluate their efficacy in hemorrhaging trauma victims.
遭受创伤性损伤的患者在初始复苏过程中可能会接受大量输血。目前,携氧溶液正在进行临床试验,以替代红细胞。尽管这些制剂可能消除许多与输血相关的问题(保质期短、感染和免疫风险、血型鉴定和交叉配血的需求),但早期的无细胞血红蛋白溶液显示出肾毒性,并与肺和全身性高血压等不良事件有关。新型聚合血红蛋白溶液在手术环境中显示出可接受的安全性,并且正在设计一些研究,其中一些由美国国防部资助,以评估其在出血性创伤受害者中的疗效。